Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Beijing
Clinical trial register · China

Clinical Trials in Beijing, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 09 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Beijing 9 Nanning 4 Harbin 4 Zhengzhou 4 Hefei 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing9 Nanning4 Harbin4 Zhengzhou4 Hefei3
All 22 locations
Target enrolment
to

Trials with a site in Beijing

9 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Allist Pharmaceuticals, Inc.
Phase 3
300
Beijing, Shandong
2024-11-19
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 3
392
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin
2024-08-07
Recruiting
Allist Pharmaceuticals, Inc.
Phase 2
88
Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2023-10-27
Recruiting
Allist Pharmaceuticals, Inc.
Phase 1/2
104
Beijing, Chongqing, Xiamen, Shenzhen, Nanning, Shijiazhuang, Harbin, Zhengzhou
2022-08-17
Recruiting
Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
NCT05288205KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma
Allist Pharmaceuticals, Inc.
Phase 1/2
240
Hefei, Beijing, Fuzhou, Xiamen, Guangzhou, Shenzhen, Harbin, Zhengzhou
2022-04-14
Active, closed
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
NCT05194995Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer
Allist Pharmaceuticals, Inc.
Phase 1/2
48
Beijing, Nanning, Harbin, Zhengzhou, Wuhan, Changsha, Nanjing, Nanchang
2022-02-17
Active, closed
Allist Pharmaceuticals, Inc.
Phase 1/2
315
Beijing
2021-07-26
Active, closed
Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLAG)
NCT03787992Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non-small Cell Lung Cancer
Allist Pharmaceuticals, Inc.
Phase 3
358
Beijing
2019-05-30
Rows per page Showing 1–9 of 9
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 9 November 2026. https://priyalifescience.com/clinical-trials-china/city/beijing

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 09 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 9 of those studies with a site in Beijing that also match the filters currently applied.

How many clinical trials are recruiting in Beijing?

6 of the 9 studies on this page are recruiting new participants as of the 09 Nov 2026, 03:17 UTC sync. A further 0 have not yet opened recruitment, 3 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Beijing), 9 studies
PhaseStudiesRecruitingShare
Phase 1/24244.4%
Phase 34344.4%
Phase 21111.1%

Most active sponsors

Lead sponsors with the most studies (Beijing)
Lead sponsorStudiesRecruiting
Allist Pharmaceuticals, Inc.96
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.